Metastatic Hepatic Epithelioid Hemangioendothelioma Treated with Olaratumab: A Falling Star Rising?

Abstract Epithelioid hemangioendothelioma (EHE) is a rare vascular malignant tumor with indolent course. Liver transplantation for local disease is the treatment of choice. In the metastatic setting there is no consensus regarding the appropriate systemic treatment. We present two cases of metastatic hepatic epithelioid hemangioendothelioma (hEHE) treated with the combination of Doxorubicin and Olaratumab. Both patients showed Stable Disease (SD) as a response, after the completion of six cycles of this combination therapy.

[1]  Robin L. Jones,et al.  ANNOUNCE: A randomized, placebo (PBO)-controlled, double-blind, phase (Ph) III trial of doxorubicin (dox) + olaratumab versus dox + PBO in patients (pts) with advanced soft tissue sarcomas (STS). , 2019, Journal of Clinical Oncology.

[2]  M. Dimopoulos,et al.  Olaratumab administered in two cases of phyllodes tumour of the breast: end of the beginning? , 2019, ESMO Open.

[3]  Matthew P. Goetz,et al.  NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY , 2019 .

[4]  S. Sleijfer,et al.  Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  G. Weinberg,et al.  Epithelioid Hemangioendothelioma as a Model of YAP/TAZ-Driven Cancer: Insights from a Rare Fusion Sarcoma , 2018, Cancers.

[6]  P. Chu,et al.  Primary liver sarcomas in the modern era: Resection or transplantation? , 2018, Journal of surgical oncology.

[7]  G. Gores,et al.  Platelet‐derived growth factor regulates YAP transcriptional activity via Src family kinase dependent tyrosine phosphorylation , 2018, Journal of cellular biochemistry.

[8]  M. McCarter,et al.  Soft Tissue Sarcoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. , 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

[9]  Jun Zhang,et al.  Apatinib for the treatment of pulmonary epithelioid hemangioendothelioma , 2017, Medicine.

[10]  V. Liska,et al.  Hepatic Epithelioid Hemangioendothelioma - a Rare Tumor and Diagnostic Dilemma. , 2017, In vivo.

[11]  M. Afrit,et al.  Aggressive primary hepatic epithelioid hemangioendothelioma: a case report and literature review , 2017, Cancer biology & medicine.

[12]  V. Mazzaferro,et al.  Hepatic Epithelioid Hemangioendothelioma and Adult Liver Transplantation: Proposal for a Prognostic Score Based on the Analysis of the ELTR-ELITA Registry , 2017, Transplantation.

[13]  Robin L. Jones,et al.  Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis , 2017, Acta oncologica.

[14]  Seung‐Mo Hong,et al.  Clinicopathological Features and Prognosis of Hepatic Epithelioid Hemangioendothelioma After Liver Resection and Transplantation. , 2016, Annals of transplantation.

[15]  Robin L. Jones,et al.  Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial , 2016, The Lancet.

[16]  F. Grosso,et al.  Sirolimus in Advanced Epithelioid Hemangioendothelioma: A Retrospective Case-Series Analysis from the Italian Rare Cancer Network Database , 2016, Annals of Surgical Oncology.

[17]  W. Yang,et al.  Epithelioid hemangioendotheliomas with TFE3 gene translocations are compossible with CAMTA1 gene rearrangements , 2016, Oncotarget.

[18]  M. Wachtel,et al.  Treatment of Hepatic Epithelioid Hemangioendothelioma: Finding Uses for Thalidomide in a New Era of Medicine , 2015, Case reports in gastrointestinal medicine.

[19]  Z. Keidar,et al.  Pazopanib for metastatic pulmonary epithelioid hemangioendothelioma—a suitable treatment option: case report and review of anti-angiogenic treatment options , 2015, BMC Cancer.

[20]  Wei Zhang,et al.  Hepatic epithelioid hemangioendothelioma metastasized to the peritoneum, omentum and mesentery: a case report. , 2015, International journal of clinical and experimental pathology.

[21]  C. Fisher,et al.  Systemic treatment options for epithelioid haemangioendothelioma: the Royal Marsden Hospital experience. , 2015, Anticancer research.

[22]  K. Dudek,et al.  Epithelioid hemangioendothelioma of the liver as a rare indication for liver transplantation. , 2014, World journal of gastroenterology.

[23]  S. Curley,et al.  Treatment sequencing strategy for hepatic epithelioid haemangioendothelioma. , 2014, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[24]  J. V. van Gorp,et al.  Epithelioid Hemangioendothelioma: clinicopathologic, immunhistochemical, and molecular genetic analysis of 39 cases , 2014, Diagnostic Pathology.

[25]  S. Pileri,et al.  Long-term durable response to lenalidomide in a patient with hepatic epithelioid hemangioendothelioma. , 2014, World journal of gastroenterology.

[26]  Xaralabos Varelas,et al.  The Hippo pathway effectors TAZ and YAP in development, homeostasis and disease , 2014, Development.

[27]  J. Gugenheim,et al.  Metastatic Hepatic Epithelioid Hemangio-Endothelioma: Long-Term Response to Sunitinib Malate , 2014, Oncology Research and Treatment.

[28]  J. Blay,et al.  Sorafenib in patients with progressive epithelioid hemangioendothelioma , 2013, Cancer.

[29]  C. Borg,et al.  Metronomic cyclophosphamide: an alternative treatment for hepatic epithelioid hemangioendothelioma. , 2013, Journal of Hepatology.

[30]  D. Indelicato.  F1000Prime recommendation of Sorafenib in patients with progressive epithelioid hemangioendothelioma: a phase 2 study by the French Sarcoma Group (GSF/GETO). , 2013 .

[31]  B. Han,et al.  Treatment of pulmonary epithelioid hemangioendothelioma with combination chemotherapy: Report of three cases and review of the literature , 2013, Oncology letters.

[32]  A. Dirican,et al.  Malignant epithelioid hemangioendothelioma progressing after chemotherapy and Interferon treatment: a case presentation and a brief review of the literature. , 2013, Journal of cancer research and therapeutics.

[33]  Vinod Ravi,et al.  Vascular Sarcomas , 2013, Current Oncology Reports.

[34]  M. von Mehren,et al.  An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[35]  E. Lerut,et al.  Epithelioid Hemangioendothelioma of the Kidney Treated with Sunitinib , 2012, Oncology Research and Treatment.

[36]  K. Shetty,et al.  Liver transplantation in the management of hepatic epithelioid hemangioendothelioma: a single-center experience and review of the literature. , 2011, Transplantation proceedings.

[37]  M. Gerstein,et al.  Identification of a Disease-Defining Gene Fusion in Epithelioid Hemangioendothelioma , 2011, Science Translational Medicine.

[38]  C. Antonescu,et al.  A novel WWTR1‐CAMTA1 gene fusion is a consistent abnormality in epithelioid hemangioendothelioma of different anatomic sites , 2011, Genes, chromosomes & cancer.

[39]  V. Ravi,et al.  Inhibiting the VEGF–VEGFR pathway in angiosarcoma, epithelioid hemangioendothelioma, and hemangiopericytoma/solitary fibrous tumor , 2010, Current opinion in oncology.

[40]  M. Chung,et al.  Pleural Epithelioid Hemangioendothelioma , 2008, Yonsei medical journal.

[41]  B. O'Neil,et al.  Response of epithelioid haemangioendothelioma to liposomal doxorubicin. , 2005, The Lancet. Oncology.

[42]  D. V. van Thiel,et al.  Successful medical treatment of an epithelioid hemangioendothelioma of liver. , 1997, Oncology.